AgomAb Therapeutics N.V. American Depositary Shares (AGMB) Stock Score, Valuation & Financial Research
AgomAb Therapeutics N.V. American Depositary Shares is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.
Quick answer for AGMB
AgomAb Therapeutics N.V. American Depositary Shares does not currently have a complete Wall Street Score. The stored market price is USD 8.84. These figures are a research snapshot, not a buy or sell recommendation.
What AgomAb Therapeutics N.V. American Depositary Shares does
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Company business and revenue
Research reporting period: 2025-12-31. A research update is not a new financial filing.
How the company makes money
AgomAb Therapeutics is a clinical-stage biopharmaceutical company that has not yet generated revenue. Its business model focuses on the research and development of novel therapeutics for fibrotic diseases, relying on capital raises and financing to fund clinical trials and operational expenses.
Products and services
- The company is developing a pipeline of product candidates, including ontunisertib (AGMB-129), an oral GI-restricted small molecule inhibitor of ALK5 for the treatment of Fibrostenosing Crohn's Disease.
Business strengths to evaluate
- Clinical-stage pipeline targeting fibrosis Source
Business risks and research considerations
- History of net losses and lack of revenue Source
- High costs associated with research and development Source
Sources: Company research source
Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.
AGMB financial snapshot
Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.
- Wall Street Score:
- Not currently available
- Stored price:
- USD 8.84
- Market capitalization:
- 435.35M (currency not supplied)
- Revenue:
- USD 0.00
- Net income:
- USD -70.93M
- Free cash flow:
- USD -58.68M
- Cash:
- USD 251.29M
- Total debt:
- USD 1.29M
- EPS:
- USD -1.45
What stands out
- Free cash flow is USD -58.68M, negative for the stored period.
- The balance sheet shows USD 251.29M of cash versus USD 1.29M of total debt, an excess of cash over debt on these two reported measures.
- The current research record carries a limited financial history warning, which should be reviewed alongside the score.
Company-specific financial comparisons
The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.
- Cash exceeds debt by USD 250M using the stored balance-sheet values. This does not include other obligations or restricted cash.
Questions worth answering for AGMB
Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.
- How long can AGMB fund negative free cash flow using its current cash position before it may need more debt or new shares?
- How is AGMB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- What specifically needs to improve for AGMB to reach sustainable profitability?
- What does the current limited financial history warning mean for the reliability or interpretation of AGMB's score?
What the numbers mean
A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.
A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-10-01.
Research-input completeness: 55% of the scoring inputs required for this public page are currently available.
How to research AGMB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.